Publikasi Scopus FKUI Tahun 2010 s/d 2020 (data Per 3 Februari 2021)

Shah S., Zilov A., Malek R., Soewondo P., Bech O., Litwak L.
7403887535;12786267500;23467111300;23475336100;6603132385;6602976695;
Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: Results from the A 1chieve observational study
2011
Diabetes Research and Clinical Practice
94
3
364
370
42
Bhatia Hospital, Bombay Mutual Terrace, 534 Sandhurst Bridge, 3rd Floor, Mumbai 400007, India; Department of Endocrinology, First Moscow State Medical University, 1 Pogodinskaya Street, Office 622, Moscow, Russian Federation; Internal Medicine, CHU Sétif, Sétif 19000, Algeria; Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jalan Diponegoro No. 71, Jakarta 10430, Indonesia; Novo Nordisk Pharmaceuticals, 18F, East Tower, World Financial Center, No. 1, East 3rd Ring Middle Road, Caoyang District, Beijing 100020, China; Endocrinology and Nuclear Medicine: Diabetes and Metabolism Section, Hospital Italiano de Buenos Aires, Lafinur 3050 Piso 8 Dpto. 2, (1425) Ciudad De Buenos Aires, Argentina
Shah, S., Bhatia Hospital, Bombay Mutual Terrace, 534 Sandhurst Bridge, 3rd Floor, Mumbai 400007, India; Zilov, A., Department of Endocrinology, First Moscow State Medical University, 1 Pogodinskaya Street, Office 622, Moscow, Russian Federation; Malek, R., Internal Medicine, CHU Sétif, Sétif 19000, Algeria; Soewondo, P., Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jalan Diponegoro No. 71, Jakarta 10430, Indonesia; Bech, O., Novo Nordisk Pharmaceuticals, 18F, East Tower, World Financial Center, No. 1, East 3rd Ring Middle Road, Caoyang District, Beijing 100020, China; Litwak, L., Endocrinology and Nuclear Medicine: Diabetes and Metabolism Section, Hospital Italiano de Buenos Aires, Lafinur 3050 Piso 8 Dpto. 2, (1425) Ciudad De Buenos Aires, Argentina
Aims: To determine the effects on quality of life after starting insulin with, or switching to, insulin analogue therapies in the 24-week, prospective, non-interventional, observational A 1chieve study conducted across four continents in people with type 2 diabetes. Methods: Health-related quality of life (HRQoL) was assessed at baseline and at 24. weeks by the validated EQ-5D questionnaire (visual analogue score [VAS] and five dimensions) in 66,726 people who had started using basal insulin detemir, mealtime insulin aspart (with or without a basal insulin) or biphasic insulin aspart 30. Results: For the overall cohort, reported HRQoL increased significantly by 13.8 points from 63.4 points at baseline to 77.2 points at 24. weeks (p< 0.001) (scale 1-100, 100 = best health imaginable). Beginning or changing insulin was associated with a significant increase in HRQoL score (+15.0 points and +11.1 points, respectively), resulting in a similar score at 24. weeks in the two populations (77.8 and 75.9 points). Reported HRQoL also increased statistically significantly in people administering any insulin analogue regimen and across all regions, although there were some marked regional differences in reported HRQoL at baseline. Conclusion: Compared with baseline scores, beginning insulin with, or switching to, insulin analogue therapies are associated with increased HRQoL. © 2011.
Insulin analogues; Quality of life; Type 2 diabetes
glucose; insulin aspart; insulin detemir; oral antidiabetic agent; adult; Africa; anxiety; article; Asia; clinical study; cohort analysis; controlled clinical trial; controlled study; daily life activity; depression; EQ-5D questionnaire; Europe; female; glycemic control; human; hypoglycemia; major clinical study; male; multicenter study; named inventories, questionnaires and rating scales; non insulin dependent diabetes mellitus; non interventional study; observational study; pain assessment; prospective study; psychologic assessment; quality of life; self care; South and Central America; statistical significance; treatment outcome; visual analog scale; walking; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; International Agencies; Prospective Studies;
01688227
DRCPE
22153568
Article
Q1